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ABSTRACT
Neutrophil-to-lymphocyte ratio (NLR) is considered a prognostic factor in 
patients with hepatocellular carcinoma (HCC). Our aim is to investigate the prognostic 
significance of NLR in patients with HCC treated with sorafenib. 
Results: Median follow-up time was 7 months. Patients were mostly in the 
intermediate (27.3%) or advanced (72.7%) BCLC stages, 38.6% had vascular 
invasion and 27.5% extrahepatic disease. A large proportion (38.9%) had been 
previously treated with TACE. Liver function was preserved: 65.8% were classed as 
Child A. Median overall survival was 7.7 months (95% CI: 5.8–9.6). In univariate 
analysis, vascular invasion (P = 0.004), ECOG-PS ≥ 1 (P < 0.001), high bilirubin  
(P < 0.001), clinical ascites (P = 0.036), BCLC stage (P = 0.004), no previous TACE 
(P = 0.041) and NRL ≥ 2.3 (P = 0.005) were predictors of poor survival. Skin toxicity  
(P = 0.039) or hypertension (P = 0.033) during treatment were related to better survival. 
In multivariate analysis NLR ≥ 2.3 [HR 1.72 (95% CI: 1.03–2.71)], hyperbilirubinemia 
[HR 3.42 (95% CI: 1.87–6.25)] and ECOG-PS ≥ 1 [HR 1.97 (95% CI: 1.19–3.26)] were 
found as independent indicators of poor overall survival. Dermatologic adverse effects 
were an indicator of good overall survival [HR 0.59 (95% CI: 0.38–0.92)].
Material and Methods: One hundred and fifty-four consecutive HCC patients 
treated with sorafenib in four different Spanish hospitals between August 2005 and 
October 2013 were analysed. Clinical, laboratory, and tumour features were obtained. 
Survival was calculated from the moment sorafenib treatment was initiated. Log-rank 
and Cox regression were used to analyse the ability of NLR to predict survival. 
Conclusions: NLR is an independent prognostic indicator for overall survival in 
HCC patients treated with sorafenib.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth 
most common malignancy and the second leading 
cause of cancer-related deaths worldwide [1]. Liver 
transplantation, radiofrequency ablation, and surgical 
resection are considered potential curative treatments 
at the early stage of the disease [1, 2]. Locoregional 
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treatments including transarterial chemoembolization 
(TACE) and radioembolization (TARE) are the mainstay 
of treatment for intermediate stage HCC, and the latter 
can be performed in the presence of macroscopic portal 
vein thrombosis [1–3]. In the advanced stage, sorafenib 
has been shown to improve survival in the first line of 
therapy [2, 4]. Recently regorafenib showed superiority 
over placebo in the second line and lenvatinib was non-
inferior compared to sorafenib in a phase III trial in the 
same stage [5]. Patients in the intermediate stage with 
disease progression or not fit for locoregional therapy are 
treated with sorafenib based on the concept of treatment 
stage migration [6].
Although tumour stages define groups of patients 
with progressively worse prognosis, patients in the same 
stage may still have heterogeneous outcomes. For the 
intermediate stage, for instance, a subclassification into 
four groups has been recently proposed [7, 8], but we lack 
universally accepted prognostic factors that may allow 
stratification of patients across tumour stages [9, 10]. In 
the advanced stage some prognostic factors have been 
identified in the last years. Baseline AST could be helpful 
in determining which patients are most likely to benefit 
from sorafenib, especially inside Child B stage [11, 12]. 
Other authors reported that the development of adverse 
effect related to sorafenib treatment (dermatologic, 
diarrhoea and hypertension) has been associated with a 
better overall survival [13, 14]. Lastly in the GIDEON 
cohort, that includes more 3202 patients, the authors 
observed that patient of advanced Child stage have a 
poor overall survival [15]. Recently, the role of systemic 
inflammation in tumour progression has been investigated 
in different types of cancers. An indirect marker of a 
systemic inflammatory response is the neutrophil-to-
lymphocyte ratio (NLR), which is defined as a ratio of the 
neutrophil to lymphocyte count in peripheral blood [16]. 
NLR has been evaluated as a prognostic factor in different 
malignancies including breast, ovarian, oesophageal, 
gastric, colorectal, kidney, and urothelial cancer [17–23]. 
In HCC, the impact of NLR on recurrence and survival 
has been evaluated in large cohorts of patients including 
those treated by surgical resection, transplantation, 
radiofrequency ablation, TACE, and TARE [16, 24–29]. In 
these studies, a high NLR predicted HCC recurrence and 
was associated with worse survival. The analysis of the 
tumour microenvironment in liver explants bearing HCC 
suggests that a high NLR is linked to an up-regulation 
of the inflammatory pathways that may confer a more 
aggressive tumour [30]. A clear cut-off value has not been 
established for NLR, and the values associated with a 
worse prognosis vary amongst different publications [31]. 
A recent review and meta-analysis suggests that NLR is a 
major prognostic factor for HCC patients and that it might 
be further incorporated into the prognostic model of HCC 
[32]. Data in sorafenib treated patients are scarce. A recent 
study including 56 patients observed that NLR represent 
a potential prognostic indicator in patients with advanced 
HCC treated with sorafenib. In this cohort a high NLR was 
associated with a lower progression free survival, but not 
with a significant change in overall survival [33]. The aim 
of our study is to investigate the prognostic significance of 
NLR in HCC patients treated with sorafenib. 
RESULTS
Baseline characteristics
One hundred and fifty four patients with HCC that 
began therapy with sorafenib in the defined period were 
studied and their baseline characteristics are shown in 
Table 1. Briefly, most patients were men (79.9%) and 
Caucasian (95.7%). Mean age at the beginning of treatment 
with sorafenib was 63 (± 11) years. Most patients (88.4%) 
were cirrhotics and the most frequent aetiologies of liver 
disease were alcohol (39.4%) and hepatitis C virus infection 
(38.6%). Child-Pugh class at the time sorafenib treatment 
was initiated was A in 65.8% of patients and B in 34.2%. 
Less than one-fifth of patients had ascites (14.8%) and 
only 3.3% had had previous encephalopathy. With respect 
to staging, 27.3% of patients were in the intermediate 
stage (BCLC B) and 72.7% in the advanced stage (BCLC 
C) respectively. A significant number of patients (38.6%) 
had macroscopic vascular invasion and nearly one fourth 
(27.5%) had metastatic extrahepatic disease. An altered 
ECOG performance status was observed in 48 patients 
with 27.2% classified as grade 1 and 5.4% as grade 2. 
Median time between diagnosis and initiation of treatment 
with sorafenib was 4 months (range 1–12). A remarkable 
proportion of patients (38.9%) had received TACE prior 
to treatment with sorafenib and nearly one fifth (18.8%) 
had been treated with TARE. Globally 61% of patients had 
received at least one treatment before starting sorafenib. 
A significant number of patients reported any side effect 
(87.9%) during treatment with sorafenib. The most 
frequent adverse event was diarrhoea (46.8%), followed by 
dermatologic side effects (44%) and hypertension (15.6%). 
Survival analysis and neutrophil-to-lymphocyte 
ratio 
Median follow-up was 7 months (IQR: 3–15 
months). During this time, 117 deaths occurred, 
corresponding to 83.6% of the study population. Median 
overall survival was 7.7 months (95%CI: 5.8–9.6 months). 
Mean neutrophil count was 3,800 (± 2,200) per microliter, 
whereas mean lymphocyte count was 1,400 (± 900) per 
microliter. Median NLR was 2.7 (1.8–4.1). ROC analysis 
and Youden’s index were used to calculate an optimal cut-
off level of 2.3. Sixty-four patients (42.4%) had a NLR 
value of less than 2.3.
Patients with NLR ≥ 2.3 had worse overall survival 
(6.3 months [95% CI: 4.3–8.3 months] vs. 12.7 months 
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Age (years) 63 ± 11 (28–86)




















6 ± 1 (5–9)
MELD 10 ± 3
Ascites 22 (14.8%)
Encephalopathy 5 (3.3%)
Albumin (g/dl) 3.6 ± 0.7
Hypoalbuminemia (≤ 3.5 g/dl) 47 (32.6%)
Creatinine (mg/dl) 0.9 ± 0.4
Bilirubin (mg/dl) 1.4 ± 0.8
Hyperbilirubinemia (≥ 2 mg/dl) 24 (15.9%)
Platelets (per microliter) 160.001 ± 93.361






Vascular Invasion 59 (36.8%)
Extrahepatic metastases 42 (27.5%)







Alphafetoprotein (ng/ml) 142 (11–1.500)
Alphafetoprotein ≥ 400 ng/ml 56 (39.4%)
Previous treated 94 (61%)
Previous TACE treatment 60 (38.9%)
Previous TARE treatment 29 (18.8%)
AST (U/L) 63 (43–120)
AST ≥ 100 U/L 45 (30.6%)
Neutrophil (per microliter) 3,800 ± 2,200
Lymphocyte (per microliter) 1,400 ± 900
Neutrophil to Lymphocyte Ratio (NLR) 2.7 (1.8–4.1)
NLR ≥ 2.3 87 (57.6%)
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[95% CI: 7.2–18.2 months]; P = 0.005) Figure 1 shows 
the Kaplan Meier Overall survival curves according to 
neutrophil-to-lymphocyte ratio. A univariate analysis was 
performed to identify factors related to overall survival. An 
advanced BCLC C stage (P = 0.005), clinical ascites (P = 
0.036), vascular invasion (P = 0.004), hyperbilirubinemia (P 
< 0.001), absence of previous TACE (P = 0.041), and ECOG 
performance status ≥ 1 (P < 0.001) were statistically associated 
with poor survival. Skin toxicity (P = 0.039) and hypertension 
(P = 0.033) during treatment with sorafenib were 
statistically associated with better survival. We did not 
observe an association between survival and Child 
score (P = 0.193), hypoalbuminemia (P = 0.264), high 
alphafetoprotein (≥ 400 ng/ml) (P = 0.158), high GOT/
AST levels (≥ 100 U/L) (P =0.059), extrahepatic disease 
(P = 0.632), hepatic encephalopathy (P = 0.903), previous 
RE (P = 0.956), or any treatment prior to sorafenib 
(P = 0.068). Univariate analysis results for overall survival 
are outlined in Table 2. A multivariate model was built 
including those variables that were statistically significant in 
the multivariate analysis: high NLR, clinical ascites, vascular 
invasion, hyperbilirubinemia, absence of previous TACE, 
ECOG performance status ≥ 1, dermatologic side effects 
and hypertension. BCLC C stage was not included to avoid 
redundance since 2 of its 3 components (vascular invasion 
and altered ECOG status were included). In this model a 
NLR ≥ 2.3 was confirmed as an independent indicator of poor 
overall survival together with ECOG performance status ≥ 
1 and hyperbilirubinemia. Dermatologic side effects were 
confirmed as independent indicator of better overall survival. 
Results of multivariate analysis are summarized in Table 3.
DISCUSSION
The interest in systemic inflammation as a poor 
prognostic marker in patients with cancer is growing 
[17–23]. An increased systemic inflammatory response 
may be associated with a poor performance status 
[34, 35]. However, in patients with HCC, the identification 
of an altered performance status due to cancer can be a 
challenge because the symptoms related to the underlying 
cirrhosis [34] and subclinical inflammation may worsen 
patient prognosis. Laboratory tests used to identify 
systemic inflammatory markers such as serum levels of 
C-reactive protein or albumin may overcome these two 
problems [28] however, these parameters might be altered 
in cirrhotic patients with or without tumour disease, 
therefore their utility is questionable. NLR is one of the 
easiest and most reliable indexes used to detect a systemic 
inflammatory response. 
NLR has been previously studied in patients 
with HCC; however, mostly in the context of surgery, 
transplantation, or TACE [24–29]. Recently the prognostic 
value of NLR has been also evaluated in a group of 
patient included in a phase II randomized trial evaluating 
tivantinib vs. placebo. In this study the authors observed 
that a baseline high NLR (greater than 3) is an independent 
prognostic biomarker in patients with HCC who are 
candidate for second-line treatments. An important finding 
was that for overall survival, no interaction was detected 
between NLR status and treatment [36]. These results 
confirm that NLR have a prognostic value regardless the 
treatment applied.
Our study is one of the largest performed in a 
European population and one of the first to demonstrate 
the prognostic value on overall survival of high NLR 
values in European patients with advanced HCC treated 
with sorafenib. A single study on a small sample of 
Chinese patients with extremely high NLR values 
found similar results [37]. Another Chinese cohort of 
205 patients those with low NLR presented lower CLIP 
score and higher 6-month survival rate (56.1 vs 25.9%) 
compared with patients with high NLR level (greater 
than 2.43). Moreover low NLR level was associated with 
favorable prognostic factors such as lower α-fetoprotein, 
alkaline phosphatase, and total bilirubin, as well as 
decreased incidence of ascites, portal vein thrombosis, and 
metastasis [38]. Nevertheless, the characteristics of the 
populations receiving sorafenib in European and Eastern 
countries are not comparable as illustrated in the wide 
difference in overall survival reported in the pivotal trials 
[4, 39]. Another recent study including 56 patients with 
advanced hepatocellular carcinoma treated with sorafenib 
observed that a high NLR (greater that 3) was associated 
with a lower progression free survival (P = 0.049), but not 
with a lower overall survival in the multivariate analysis 
(P = 0.062), probably because the number of patients 
included [33]. 
Similar results were observed in a Brazilian cohort 
of 105 patients treated with sorafenib. In this study the 
authors observed that a high NLR (greater than 3.5) 
was associated with a worse prognosis [40]. Our study 
confirms and complements the results of these studies.
Recently a large cohort of 442 patients treated with 
sorafenib among three different countries demonstrated 
that the integration of inflammatory markers, clinical 
features and treatment related side-effects could help 
stratifying patients according to survival. Particularly 
the authors observed that previously-treated HCC, 
Cancer of Liver Italian Program (CLIP) score, baseline 
red cell distribution width and NLR were significant 
independent risks for shorter survival, whilst sorafenib-
related diarrhoea was associated with prolonged survival. 
Finally the authors purpose a novel prognostic index 
combining CLIP score with inflammatory marker and 
treatment-related side-effects has good accuracy for 
predicting survival in patients with advanced HCC treated 
with sorafenib [41]. Our data support the results and the 
hypothesis of this study: clinical features, inflammatory 
markers and treatment related adverse are independent 
predictors of survival in advanced HCC patient treated 
with sorafenib.
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Table 2: Overall survival-univariate analysis




















































































































Table 3: Overall Survival-Multivariate Analysis (adjusted for NLR ≥ 2.3, ECOG-PS ≥ 1, 
dermatological adverse events, hyperbilirrubinemia, hypertension, presence of vascular invasion, 
clinical ascites and previous TACE)
Variable P HR (95% CI)
NLR ≥ 2.3 0.019 1.72 (1.09–2.71)
ECOG-PS ≥ 1 0.008 1.97 (1.19–3.26)
Dermatological adverse events 0.019 0.59 (0.38–0.92)
Hyperbilirrubinemia (≥ 2 mg/dl) < 0.001 3.42 (1.87–6.25)
Figure 1: Overall survival according to neutrophil-to-lymphocyte ratio.
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In our study development of adverse effect related 
to sorafenib could help to identify patients with a better 
overall survival, as previously described [13, 14]. 
Particulary development of dermatologic adverse effects 
related to sorafenib is an independent predictor of good 
overall survival in our cohort. 
The characteristics of our cohort are those expected 
in a population of patients treated with sorafenib [8]. 
The NLR cut-off level in our study is consistent with 
other publications in which ROC curves were used to 
identify such value [28, 42]. The higher cut-off values 
observed in other studies, especially those involving 
Asian populations, are in line with the differing patient 
characteristics mentioned above [30, 37, 43]. Indeed, 
a recent meta-analysis that included 15 studies and 
investigated the prognostic impact of NLR on survival 
with different HCC treatments, was unable to establish 
a clear cut-off value [43]. Results from another recent 
review and meta-analysis support the incorporation of 
NLR into the prognostic model of HCC, but did not set a 
clear cut-off [32].
In our analysis, NLR emerged as a predictor of 
overall survival. Overall, survival of patients with a NLR 
≥ 2.3 was significantly reduced compared to patients with 
a lower NLR (6.29 vs. 12.72 months). Not surprisingly, 
factors most strongly associated with survival were 
an advanced BCLC stage and particularly one of their 
components: altered performance status. 
We did not observe that alpha-fetoprotein levels 
were associated with poor survival, probably reflecting 
that this variable is a better predictor when used in a 
dynamic way [8, 44]. 
Those patients that received sorafenib after having 
progressed to TACE had a better outcome. The likely 
cause of this observation is that those patients that are still 
eligible for sorafenib after TACE failure represent a select 
group of tumours with a less aggressive behaviour. There 
may be also a confounding effect by indication bias in this 
group (Reference). Previous TACE treatment could select 
a group of patients with better survival because of their 
clinical characteristics rather than TACE treatment itself. 
This hypothesis would be supported by the fact that prior 
TACE was not independently associated with mortality in 
the multivariate analysis.
In conclusion, our results indicate that a high 
NLR is a strong and easily available predictor of overall 
survival in patients with intermediate to advanced HCC 
treated with sorafenib. Along with other studies involving 
patients at different stages and those administered 
different therapies, our results show that NLR is a simple, 
objective, inexpensive, and readily available biochemical 
marker that may be useful in refining the prognosis 
of individual patients with HCC. Quite importantly, 
NLR could help stratify these patients in clinical trials 




All consecutive patients with HCC that began 
therapy with sorafenib between August 2005 and October 
2013 in four different Spanish hospitals were considered 
for analysis. The diagnosis of HCC was based on non-
invasive criteria [2, 45] or histology. Tumour staging was 
determined according to the Barcelona clinic liver cancer 
(BCLC) classification [2, 45]. Patients with previous 
liver transplantation, stage A or D of BCLC classification 
and stage C of Child classification were excluded from 
analysis. The data were collected from clinical records in 
an anonymous registry and were retrospectively analysed. 
The collection of data in the registry has the approval 
of the local ethics committee (CEICA, Comité Ético de 
Investigación Clinica de Aragón, Zaragoza, Spain).
Baseline patient characteristics were obtained 
at the beginning of sorafenib treatment. Demographic 
characteristics included age, gender, and ethnic group. 
Hepatic disease features included the presence of cirrhosis; 
aetiology of liver disease; presence and degree of ascites 
and encephalopathy; serum levels of albumin, bilirubin, 
AST/GOT, creatinine, and alpha-fetoprotein; platelet 
count; INR; and prothrombin activity as well as composite 
scores such as Child-Pugh stage and MELD score. Tumour 
characteristics included BCLC stage, number of nodules, 
size of the largest nodule, presence of vascular invasion 
and metastases, ECOG performance status, and previous 
loco-regional treatment. BCLC and Child stages were 
analysed as qualitative variables. NLR was calculated 
as the ratio of neutrophil count to lymphocyte count in 
peripheral blood measured just prior to the beginning 
of sorafenib treatment. Development of adverse events 
(dermatologic manifestations, hypertension or diarrhoea) 
during treatment with sorefenib was collected. Overall 
survival was calculated from the date Sorafenib was 
initiated to the date of death or last follow-up visit.
Statistical analysis
Qualitative variables are expressed as a percentage, 
whereas continuous variables are expressed as mean (± 
standard deviation) if they had a normal distribution and 
as median (interquartile range) if otherwise. Survival plots 
were calculated using the Kaplan-Meier method. The Log-
Rank method was used for univariate analysis and the 
Cox-regression model was used for multivariate analysis. 
The likelihood ratios forward stepwise method was used 
for the multivariate Cox proportional analysis. The NLR 
cut-off level was calculated using the receiver operator 
curve (ROC) analysis and Youden’s index with death as 
test variable [28, 42]. For AFP (400 ng/ml) and AST/
GOT (100 U/L) cut off levels we used those previously 
described [11, 12, 46]. A p-value of less than 0.05 was 
Oncotarget103084www.impactjournals.com/oncotarget
considered statistically significant. SPSS version 22 (SPSS 
Inc., Chicago, IL, USA, Universidad de Zaragoza) was 
used for all statistical analyses. 
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